Back to results
US 2025/0179068 A1Published application
Synthesis of kras g12c inhibitor compound
AssigneeAmgen Inc.
InventorsAndrew T. PARSONS, Matthew G. BEAVER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
Claims25
A process of preparing a compound of Formula (6A):
- comprising admixing (2-fluoro-6-methoxyphenyl) boronic acid with BBr3 in at least one solvent to provide the compound of Formula (6A).
A process of preparing a compound of Formula 7
- comprising admixing a compound of Formula (6A):
- with a compound of Formula (6):
- in the presence of a catalyst and potassium acetate to form the compound of Formula (7).
Dependencies are inferred from the claim text.